The study analyzed 205,065 first-time visits for ADHD and 933,455 first-time visits for anxiety from Jan. 1, 2020, through March 31, 2023, to assess the medication prescribing rates for telehealth versus in-person visits.
Stimulants are considered a first-line treatment for ADHD and are classified as controlled substances. They are not typically prescribed for anxiety, which was used as a comparison point.
The study found that:
- Prescribing rates for ADHD medication within 30 days of initial diagnosis are similar for both telehealth and in-person office visits.
- Anti-anxiety medication prescriptions within 30 days of a telehealth or in-person visit were also found to be similar; however, anti-anxiety medications were prescribed less often than ADHD medications, according to the June 27 study.
This comes at a time when the Drug Enforcement Agency tried to propose a rule that would require physicians to conduct an in-person evaluation prior to prescribing controlled substances via telemedicine, though after significant pushback, the DEA granted a temporary extension allowing physicians to prescribe controlled substances virtually without an in-person evaluation.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
